FLT3 (R595_E596insEY)

FLT3 · Variant type: indel · HGVS: p.R595_E596insEY

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Gilteritinib	99.6%	0.4%	88.97
2	Sunitinib	99.3%	0.7%	91.73
3	Brigatinib	98.8%	1.2%	82.96
4	Pacritinib	98.4%	1.6%	88.64
5	Ponatinib	98.0%	2.0%	78.23
6	Fostamatinib	97.2%	2.8%	96.74
7	Quizartinib	96.9%	3.1%	99.50
8	Selpercatinib	96.8%	3.2%	96.72
9	Defactinib	95.8%	4.2%	92.68
10	Pralsetinib	95.4%	4.6%	93.43
11	Nintedanib	93.6%	6.4%	90.23
12	Fedratinib	92.4%	7.6%	96.21
13	Avapritinib	92.1%	7.9%	97.73
14	Entrectinib	91.0%	9.0%	93.69
15	Sorafenib	90.7%	9.3%	96.72
16	Cabozantinib	87.5%	12.5%	92.73
17	Alectinib	83.9%	16.1%	95.49
18	Canertinib	80.7%	19.3%	96.49
19	Rabusertib	74.7%	25.3%	98.74
20	Erlotinib	71.8%	28.2%	99.75
21	Vandetanib	67.0%	33.0%	95.74
22	Tivozanib	63.8%	36.2%	92.42
23	Ripretinib	62.6%	37.4%	92.95
24	Pexidartinib	58.0%	42.0%	99.49
25	Osimertinib	56.9%	43.1%	97.24

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Gilteritinib	99.6%	99.2%	+0.4%
Sunitinib	99.3%	98.7%	+0.5%
Brigatinib	98.8%	98.1%	+0.7%
Pacritinib	98.4%	93.6%	+4.8%
Ponatinib	98.0%	97.9%	+0.1%
Fostamatinib	97.2%	97.2%	-0.1%
Quizartinib	96.9%	97.9%	-0.9%
Selpercatinib	96.8%	96.1%	+0.7%
Defactinib	95.8%	94.6%	+1.2%
Pralsetinib	95.4%	97.6%	-2.2%
Nintedanib	93.6%	95.2%	-1.6%
Fedratinib	92.4%	98.2%	-5.8%
Avapritinib	92.1%	88.6%	+3.5%
Entrectinib	91.0%	96.1%	-5.1%
Sorafenib	90.7%	97.3%	-6.7%
Cabozantinib	87.5%	95.0%	-7.5%
Alectinib	83.9%	84.5%	-0.6%
Canertinib	80.7%	86.3%	-5.6%
Rabusertib	74.7%	—	—
Erlotinib	71.8%	—	—
Vandetanib	67.0%	—	—
Tivozanib	63.8%	—	—
Ripretinib	62.6%	—	—
Pexidartinib	58.0%	—	—
Osimertinib	56.9%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 15.4ms